Meeting
2021 ASCO Annual Meeting
Differential impact of different TP53 gain-of-function mutations on overall survival of patients with metastatic colorectal cancer: Results from a large integrated healthcare system.
Authors
Minggui Pan
Kaiser Permanente, Dept of Medical Oncology, Santa Clara, CA
Minggui Pan , Chen Jiang , Pamela Tse , Elaine Chung , Aleyda Solorzano , Wenwei Hu , Thach-Giao Truong , Amit Arora , Tilak Kumar Sundaresan , Jennifer Marie Marie Suga , Laurel A. Habel , Sachdev P. Thomas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3585)
DOI
10.1200/JCO.2021.39.15_suppl.3585
Abstract #
3585
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The prognostic impact of RAS and TP53 mutation according to primary tumor location in colorectal liver metastases.
First Author: Yongjun Cha
Poster
2022 ASCO Annual Meeting
The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).
First Author: Jenny F. Seligmann
Poster
2020 ASCO Virtual Scientific Program
Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.
First Author: Christos Stelios Karapetis
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera